Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers.
Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM. · 2019
Read Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers. by Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6355990.txt.
Introduction
Baxter and co-authors test how three fermentable fibers change gut output in people. Their study appeared in mBio. Gut bacteria ferment fiber into short-chain fatty acids. Butyrate, one of them, guards gut health and immunity. Not all fibers raise it equally, though. The team ran dietary interventions with three fibers.
Responses depended on each person's starting microbes. Some people raised butyrate, others did not. Two bacterial species seemed required for the resistant starch effect. They are Ruminococcus bromii and a Clostridium species. Bifidobacteria broke down fibers well in the tests. Yet they did not drive the butyrate rise short term. The authors stress personalization in fiber advice. A supplement only works if the right microbes are present.
Catalog record
| CREATOR | Baxter NT, Schmidt AW, Venkataraman A, Kim KS, Waldron C, Schmidt TM. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Dynamics of Human Gut Microbiota and Short-Chain Fatty Acids in Response to Dietary Interventions with Three Fermentable Fibers By Nielson T. Baxter, Alexander W. Schmidt, Arvind Venkataraman, Kwi S. Kim, Clive Waldron, Thomas M. Schmidt, Martin J. Blaser, Robert Britton, Jens Walter Published in: mBio DOI: 10.1128/mBio.02566-18 ABSTRACT These results reveal that not all fermentable fibers are equally capable of stimulating SCFA production, and they highlight the importance of the composition of an individual’s microbiota in determining whether or not they respond to a specific dietary supplement. In particular, R. bromii or C. chartatabidum may be required for enhanced butyrate production in response to RS. Bifidobacteria, though proficient at degrading RS and inulin, may not contribute to the butyrogenic effect of those fermentable fibers in the short term. INTRODUCTION Short-chain fatty acids (SCFAs) are major end products of bacterial fermentation in the human colon and are known to have wide-ranging impacts on host physiology. Butyrate in particular is important for maintaining health via regulation of the immune system (1), maintenance of the epithelial barrier (2, 3), and promotion of satiety following meals (4). It may be protective against several diseases, including colorectal cancer (5), inflammatory bowel disease (6), graft-versus-host disease (7), diabetes (8), and obesity (8, 9). Therefore, stimulating butyrate production by the colonic microbiome could be useful for sustaining health and treating diseases. One strategy for stimulating butyrate production is to supplement the diet with carbohydrates that are resistant to degradation by human enzymes but can be metabolized by select bacteria in the colon. We previously demonstrated that one such resistant starch (RS) prepared from potatoes (RPS) could increase average fecal butyrate in healthy, young adults (10). Others have reported increased butyrate in response to inulin in humans and resistant starch from maize (RMS) in mice (11, 12). A critical challenge to these potential therapies is the variable responses between individuals, likely influenced by differences in the composition of their gut microbiota. To capture this variability, large numbers of subjects are required. We analyzed samples from 174 university students who consented to participate in and then successfully completed this short-term interventional study. This young cohort provided a wide diversity of gut communities without the additional complications of chronic health conditions such as obesity, type 2 diabetes, or cardiovascular disease that are related to altered microbiome structure and function (13, 14). We did not ask the participants to make changes to their diets other than taking the supplements provided, even though we recognize different diets also have a profound impact on microbiome structure and function. Our objective was to determine how these different resistant polysaccharides affected the concentrations of SCFAs when added to “normal” diets, not just under one dietary regimen. With this number of participants, we were able to evaluate three different resistant polysaccharides and an amylase-sensitive polysaccharide as a negative control. Understanding the butyrogenic effect of these supplements and specific gut bacteria is important for designing more broadly effective therapies and predicting which individuals are likely to benefit from them. More generally, defining metabolic interactions among gut microbes enhances our understanding of the assembly, maintenance, and outputs from the gut microbiome. Identifying butyrogenic configurations of the microbiome is challenging because several different bacteria (or combinations of bacteria) may be involved in the multistep process. Many bacteria in the colon are involved in the degradation of dietary fiber, the complex mixture of plant polysaccharides that is not susceptible to host enzymes (15, 16). However, many of these bacteria are specialists, attacking specific bonds in specific types of polymers (17–19). Only a limited number of gut bacteria may be able to degrade any given resistant polysaccharide that is used as a dietary supplement. Primary degraders depolymerize specific polysaccharides to mono-, di-, and oligosaccharides that they can take up and ferment themselves to acidic end products such as acetate or lactate (20). Their selective growth on the dietary supplement should result in a higher relative abundance in fecal communities. However, most resistant starch degraders are not among known butyrate producers (19, 21). Thus, for these supplements to stimulate butyrate production, the activities of additional organisms would be required. These secondary fermenters capture degradation and fermentation products from primary degraders and metabolize them into new molecules, including butyrate (Fig. 1). However, if primary degraders use the supplements efficiently, only a fraction of the carbon and energy they contain may become available to the secondary fermenters. Therefore, increases in the relative abundance of butyrate producers may be more difficult to detect, but their metabolic activity could still be evidenced by an increase in fecal butyrate. [Figure: Proposed model of metabolites and microbes that catalyze the flow of carbon from resistant polysaccharides to butyrate. There are cultivated strains from the gut microbiome that possess the metabolic activities proposed for the species listed.] Candidates for performing one or more of the steps in Fig. 1 in vivo have already been identified by their metabolic capabilities in vitro. For example, Ruminococcus bromii and Bifidobacterium adolescentis have been shown to degrade resistant starches (22). There have been claims that other species degrade resistant starches, but they are less compelling because they either involved starch preparations that could include sensitive as well as resistant fractions (23) or because the evidence was indirect (e.g., binding to starch granules [24]) or the presence of DNA sequences encoding amylase-like GH13 domains (25). The ability to degrade inulin in vitro has been demonstrated for some species of Bifidobacterium (though not all strains) (26) and by several members of the Lachnospiraceae and Ruminococcaceae families in the phylum Firmicutes (27). These two families include most of the known butyrate producers (21). The most abundant of the butyrate producers in the human gut are Eubacterium rectale and Faecalibacterium prausnitzii, both of which are capable of degrading inulin and producing butyrate from it (27). E. rectale has been shown incapable of degrading resistant starches unless they are heat treated to denature some of the crystal structure (22). Such rigorous tests have not been reported to our knowledge for F. prausnitzii. In vitro studies have also demonstrated that combinations of primary degraders and secondary bacteria can produce butyrate from resistant polysaccharides by cross feeding. For example, Eubacterium rectale can grow on degradation products of RS released by R. bromii, and several species of Roseburia and F. prausnitzii have been cross-fed by Bifidobacterium spp. (20, 22, 28, 29). Bifidobacteria also promote butyrate production by another select group of bacteria because they produce both acetate and lactate via a unique fermentation pathway known as the Bifid shunt (30). This combination of end products can be converted into butyrate by Eubacterium hallii, Anaerostipes caccae, or Anaerostipes hadrus (31, 32). These known degraders and butyrate producers were targeted for evaluation in this dietary intervention, but we also analyzed the entire community of fecal bacteria to identify any organisms that had not previously been associated with the metabolism of these fermentable fibers. We attempted to address four major issues.Do the three resistant polysaccharides stimulate butyrate production in this population of healthy, young individuals? If so, do they have similar impacts on butyrate production?Which gut bacteria respond to these dietary additions by increasing in relative abundance? Can we identify any species that were